Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A

References

• Berntorp E, Fischer K, Hart DP, et al. Haemophilia. Nat Rev Dis Primers. 2021;7(1):45. doi:10.1038/s41572-021-00278-x
   PubMed Web of Science ®Google Scholar
• Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540–546. doi:10.7326/M19-1208
   PubMed Web of Science ®Google Scholar
• van Galen KPM, d’Oiron R, James P, et al. A new hemophilia carrier nomenclature to define hemophilia in women and girls: communication from the SSC of the ISTH. J Thromb Haemost. 2021;19(8):1883–1887. doi:10.1111/jth.15397
   PubMed Web of Science ®Google Scholar
• d’Oiron R, O’Brien S, James AH. Women and girls with haemophilia: lessons learned. Haemophilia. 2021;27(S3):75–81. doi:10.1111/hae.14094.
   PubMedGoogle Scholar
• Mannucci PM, Tuddenham EGD. The hemophilias – from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773–1779. doi:10.1056/NEJM200106073442307.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(S6):1–158. doi:10.1111/hae.14046
   PubMed Web of Science ®Google Scholar
• Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia a. J Thromb Haemost. 2009;7(3):413–420. doi:10.1111/j.1538-7836.2008.03270.x
   PubMed Web of Science ®Google Scholar
• den Uijl IEM, Fischer K, van der Bom JG, et al. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia. 2011;17(1):41–44. doi:10.1111/j.1365-2516.2010.02383.x
   PubMed Web of Science ®Google Scholar
• Soucie JM, Monahan PE, Kulkarni R, et al. The frequency of joint hemorrhages and procedures in nonsevere hemophilia a vs B. Blood Adv. 2018;2(16):2136–2144. doi:10.1182/bloodadvances.2018020552
   PubMed Web of Science ®Google Scholar
• Manco-Johnsen MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Eng J Med. 2007;357(6):535–544. doi:10.1056/NEJMoa067659
   PubMed Web of Science ®Google Scholar
• Kloosterman FR, Zwagemaker AF, Bagot CN, et al. The bleeding phenotype in people with nonsevere hemophilia. Blood Adv. 2022;6(14):4256–4265. doi:10.1182/bloodadvances.2022007620
   PubMed Web of Science ®Google Scholar
• Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015;125(13):2038–2044. doi:10.1182/blood-2015-01-528414.
   PubMed Web of Science ®Google Scholar
• Vandieijen G, Tans G, Rosing J, et al. The role of phospholipid and factor-VIIIa in the activation of bovine factor X. J Biol Chem. 1981;256(7):3433–3442. doi:10.1016/S0021-9258(19)69627-4
   PubMed Web of Science ®Google Scholar
• Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature. 1984;312(5992):326–330. doi:10.1038/312326a0
   PubMed Web of Science ®Google Scholar
• Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA-encoding human antihemophilic factor. Nature. 1984;312(5992):342–347. doi:10.1038/312342a0
   PubMed Web of Science ®Google Scholar
• Everett LA, Cleuren ACA, Khoriaty RN, et al. Murine coagulation factor VIII is synthesized in endothelial cells. Blood. 2014;123(24):3697–3705. doi:10.1182/blood-2014-02-554501
   PubMed Web of Science ®Google Scholar
• Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem. 1988;263(13):6352–6362. doi:10.1016/S0021-9258(18)68793-9.
   PubMed Web of Science ®Google Scholar
• Stennicke HR, Kjalke M, Karpf DM, et al. A novel B-domain O-glycoPegylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood. 2013;121(11):2108–2116. doi:10.1182/blood-2012-01-407494
   PubMed Web of Science ®Google Scholar
• Yee A, Gildersleeve RD, Gu SF, et al. A von Willebrand factor fragment containing the D ’ D3 domains is sufficient to stabilize coagulation factor VIII in mice. Blood. 2014;124(3):445–452. doi:10.1182/blood-2013-11-540534.
   PubMed Web of Science ®Google Scholar
• Fuller JR, Knockenhauer KE, Leksa NC, et al. Molecular determinants of the factor VIII/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy. Blood. 2021;137(21):2970–2980. doi:10.1182/blood.2020009197
   PubMed Web of Science ®Google Scholar
• Turecek PL, Johnsen JM, Pipe SW, et al. Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia. Haemophilia. 2020;26(4):575–583. doi:10.1111/hae.14078.
   PubMed Web of Science ®Google Scholar
• Fischer K, Pendu R, van Schooten CJ, et al. Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients. PLoS ONE. 2009;4(8):e6745. doi:10.1371/journal.pone.0006745
   PubMed Web of Science ®Google Scholar
• Pipe SW, Montgomery RR, Pratt KP, et al. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia a. Blood. 2016;128(16):2007–2016. doi:10.1182/blood-2016-04-713289
   PubMed Web of Science ®Google Scholar
• Franchini M. The modern treatment of haemophilia: a narrative review [Review]. Blood Transf. 2013;11(2):178–182.
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Viral safety of coagulation factor concentrates: memoirs from an insider. J Thromb Haemost. 2018;16(4):630–633. doi:10.1111/jth.13963.
   PubMed Web of Science ®Google Scholar
• Lambert T, Benson G, Dolan G, et al. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol. 2018;9(9):295–308. doi:10.1177/2040620718796429
   PubMed Web of Science ®Google Scholar
• Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia a patients. Blood. 2012;119(13):3031–3037. doi:10.1182/blood-2011-09-382846
   PubMed Web of Science ®Google Scholar
• Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia a. Blood. 2015;126(9):1078–1085. doi:10.1182/blood-2015-03-630897
   PubMed Web of Science ®Google Scholar
• Butterfield JSS, Hege KM, Herzog RW, et al. A molecular revolution in the treatment of hemophilia. Mol Ther. 2020;28(4):997–1015. doi:10.1016/j.ymthe.2019.11.006
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia a without inhibitors. N Engl J Med. 2018;379(9):811–822. doi:10.1056/NEJMoa1803550
   PubMed Web of Science ®Google Scholar
• Kizilocak H, Marquez-Casas E, Malvar J, et al. Determining the approximate factor VIII level of patients with severe haemophilia a on emicizumab using in vivo global haemostasis assays. Haemophilia. 2021;27(5):730–735. doi:10.1111/hae.14359
   PubMed Web of Science ®Google Scholar
• Pipe SW, Gonen-Yaacovi G, Segurado OG. Hemophilia a gene therapy: current and next generation approaches. Expert Opin Biol Ther. 2022;22(9):1099–1115. doi:10.1080/14712598.2022.2002842.
   PubMed Web of Science ®Google Scholar
• Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089–1094. doi:10.1182/bloodadvances.2021006119
   PubMed Web of Science ®Google Scholar
• Chhabra ES, Liu TY, Kulman J, et al. BIVV001, a new class of factor VIII replacement for hemophilia a that is independent of von Willebrand factor in primates and mice. Blood. 2020;135(17):1484–1496. doi:10.1182/blood.2019001292
   PubMed Web of Science ®Google Scholar
• Schellenberger V, Wang CW, Geething NC, et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol. 2009;27(12):1186–1190. doi:10.1038/nbt.1588
   PubMed Web of Science ®Google Scholar
• Demers M, Aleman MM, Kistanova E, et al. Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII. J Thromb Haemost. 2022;20(7):1674–1683. doi:10.1111/jth.15741.
   PubMed Web of Science ®Google Scholar
• Konkle BA, Shapiro AD, Quon DV, et al. BIVV001 fusion protein as factor VIII replacement therapy for hemophilia a. N Eng J Med. 2020;383:1018–1027.
   PubMed Web of Science ®Google Scholar
• Staber JM, Lissitchkov T, Konkle BA, et al. Efanesoctocog alfa half-life and clearance are independent of von Willebrand factor in severe hemophilia A: a post hoc analysis from phase 1/2a Studies. Blood. 2021;138(Supplement 1):1035–1035. doi:10.1182/blood-2021-148534
   Google Scholar
• von Drygalski A, Chowdary P, Kulkarni R, et al. Efanesoctocog alfa prophylaxis for patients with severe hemophilia a. N Engl J Med. 2023;388(4):310–318. doi:10.1056/NEJMoa2209226.
   PubMed Web of Science ®Google Scholar
• Altuviiio (efanesoctocog alfa) U.S. Prescribing Information; 2023. [cited 2023 Mar 15]. Available from: https://www.fda.gov/media/165594/download.
   Google Scholar
• Klamroth R, von Drygalski A, Herman C, et al. Perioperative management with efanesoctocog alfa in patients with hemophilia a in the phase 3 XTEND-1 study. Haemophilia. 2023;29(Suppl 1):87–88.
   Google Scholar
• Kitchen S, Tiefenbacher S, Gosselin R. Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies. Sem Thromb Hemost. 2017;43(3):331–337. doi:10.1055/s-0037-1598058.
   PubMed Web of Science ®Google Scholar
• Muller J, Miesbach W, Pruller F, et al. An update on laboratory diagnostics in haemophilia a and B. Haemostaseologie. 2022;42(4):248–260. doi:10.1055/a-1665-6232
   PubMedGoogle Scholar
• Young GA, Perry DJ; International Prophylaxis Study Group. Laboratory assay measurement of modified clotting factor concentrates: a review of the literature and recommendations for practice. J Thromb Haemost. 2019;17(4):567–573. doi:10.1111/jth.14394.
   PubMed Web of Science ®Google Scholar
• Pipe S, Sadeghi-Khomani A, Konkle B, et al. Efanesoctocog alfa activity assessment with one-stage clotting (OSA) and chromogenic substrate (CSA) factor VIII assays. Haemophilia. 2023;29(S1):32. doi:10.1111/hae.14675
   Google Scholar
• James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease [Article]. Blood Adv. 2021;5(1):280–300. doi:10.1182/bloodadvances.2020003265
   PubMed Web of Science ®Google Scholar
• Shanmukhaiah C, Jijina F, Kannan S, et al. Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): report of two cases and review of literature. Haemophilia. 2022;28(2):286–291. doi:10.1111/hae.14491
   PubMed Web of Science ®Google Scholar
• Eloctate [antihemophilic factor (recombinant) Fc fusion protein] U.S. prescribing information. [cited 2023 Mar 15]. Available from https://www.fda.gov/media/88746/download.
   Google Scholar
• Adynovate [antihemophilic factor (recombinant, PEGylated)] U.S. prescribing information. [cited 2023 Mar 15]. Available from https://www.fda.gov/media/94470/download.
   Google Scholar
• Jivi [antihemophilic factor (recombinant) PEGYlated-aucl] U.S. prescribing information. [cited 2023 Mar 15]. Available from https://www.fda.gov/media/115934/download.
   Google Scholar
• Esperoct [antihemophilic factor (recombinant) glycopegylated-exei U.S. prescribing information. [cited 2023 Mar 15]. Available from https://www.fda.gov/media/120351/download.
   Google Scholar